Atopic dermatitis (AD) is a chronically recurrent inflammatory skin disorder characterized by pruritus, a specific distribution, and a family history. It has recently been reported that the incidence of AD has increased in Korea.\(^1,2\) Pruritus, sleep loss, dietary restrictions, and psychosocial factors significantly decrease the quality of life for AD patients.\(^1,4\) Recently, the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma, and Immunology published the PRACTALL consensus report for the diagnosis and treatment of AD in children and adults.\(^5\) The report suggests a stepwise management that includes the addition of multiple therapeutic agents on the basis of the disease severity.

The PRACTALL consensus report defines severe or recalcitrant AD as AD that cannot be controlled with topical treatment.\(^6\) In the 2009 Korean Work Group Report on the treatment of severe/recalcitrant AD, severe AD is defined as AD with a SCORAD index higher than 50 and that cannot be controlled with conventional treatment,\(^7\) while the 2008 Guideline of Atopic Dermatitis in Korean Children defines severe AD by a SCORAD index higher than 40.\(^8\) Specific criteria for the definition of recalcitrant/severe AD are necessary.

For the management of severe AD, the PRACTALL consensus report recommends systemic therapy such as antimicrobial treatment, systemic corticosteroids, cyclosporin A, azathioprine, anti-histamines, phototherapy, and immunotherapy. Several reports, including the 2009 Korean Work Group Report, have described intravenous immunoglobulin (IVIg) treatment as one of various immunoregulatory treatments. Nevertheless, this treatment was not included in the PRACTALL report.\(^7,8,10\)

IVIg treatment displays immunomodulatory and anti-inflammatory properties, and its effectiveness in several immune-mediated conditions such as Kawasaki disease and idiopathic thrombocytopenic purpura has been demonstrated.\(^11\) IVIg is considered a candidate for the treatment of AD because of its ability to downregulate T-cell function, particularly interleukin-4 production.\(^12,13\) A small number of observations on the efficiency of IVIg in AD have been reported, but prospective and randomized studies for its clinical efficiency in childhood AD are sparse. A randomized, placebo-controlled prospective study in childhood AD patients is therefore required.\(^14\)

Jee et al.\(^14\) recently reported therapeutic effects of IVIg in childhood AD; however, this study involved moderate to severe AD patients, and it did not include severe AD patients because the disease severity might have affected the treatment results. Further randomized studies with strict criteria for recalcitrant/severe AD are warranted. In addition, the IVIg effective dose, the dosing interval for initiation and maintenance, the identification of biomarkers (e.g., ECP, ICAM-1, and IL-5/INF-gamma) to determine efficiency, and clear criteria for IVIg indications all require consideration.

Currently, we lack evidence-based data supporting the use of IVIg and other immunomodulators in childhood AD. Before IVIg can be recommended, its cost-benefit ratio, course, duration, and adverse reactions compared with alternative therapeutic options must be determined. The effects of novel therapies such as IVIg for recalcitrant/severe AD patients should be verified through repeated research and numerous research discussions.

REFERENCES

1. Suh M, Kim HH, Sohn MH, Kim KE, Kim C, Shin DC. Prevalence of allergic diseases among Korean school-age children: a nationwide

Correspondence to: Kyu-Earn Kim, MD, PhD, Department of Pediatrics, Gangnam Severance Hospital, Yonsei University College of Medicine, 712 Eonjuro, Gangnam-gu, Seoul 135-720, Korea. Tel: +82-2-3461-9473; E-mail: kekim@yuhs.ac

Received: March 11, 2011; Accepted: March 14, 2011

* There are no financial or other issues that might lead to conflict of interest.
cross-sectional questionnaire study. J Korean Med Sci 2011;26:332-8.
2. Hong SJ, Ahn KM, Lee SY, Kim KE. The prevalences of asthma and allergic diseases in Korean children. Pediatr Allergy Respir Dis 2008;18:15-25.
3. Holm EA, Wulf HC, Stegmann H, Jemec GB. Life quality assessment among patients with atopic eczema. Br J Dermatol 2006;154:719-25.
4. Cho HN, Hong S, Lee SH, Yum HY. Nutritional status according to sensitized food allergens in children with atopic dermatitis. Allergy Asthma Immunol Res 2011;3:53-7.
5. Akdis CA, Akdis M, Bieber T, Bindslev-Jensen C, Boguniewicz M, Eigenmann P, Hamid Q, Kapp A, Leung DY, Lipozencic J, Luger TA, Muraro A, Novak N, Platts-Mills TA, Rosenwasser L, Scheynius A, Simons FE, Spiegel J, Turjannaa K, Wahn U, Weidinger S, Werfel T, Zuberbier T, European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology. PRACTALL Consensus Report. J Allergy Clin Immunol 2006;118:152-69.
6. Long CC, Funnell CM, Collard R, Finlay AY. What do members of the National Eczema Society really want? Clin Exp Dermatol 1993;18:516-22.
7. Park JS, Kim BJ, Park Y, Lee SY, Kim WK, Kim JE, Yum HY, Nahm DH, Kim HH, Hong SJ, Oh JW, Lee AY, Kim KH, KAAACI Work Group on Severe/Recalcitrant Atopic Dermatitis. KAAACI work group report on the treatment of severe/recalcitrant atopic dermatitis. Korean J Asthma Allergy Clin Immunol 2010;30:255-70.
8. Korean Academy of Pediatric Allergy and Respiratory Disease. Guideline of atopic dermatitis in Korean children. 1st ed. Seoul: Kwangmun Press; 2008.
9. Kimata H. High dose gammaglobulin treatment for atopic dermatitis. Arch Dis Child 1994;70:335-6.
10. Gelfand EW, Landwehr LP, Esterl B, Mazer B. Intravenous immune globulin: an alternative therapy in steroid-dependent allergic diseases. Clin Exp Immunol 1996;104 Suppl 1:61-6.
11. Hanna K, Poulin-Costello M, Preston M, Maresky N. Intravenous immune globulin use in Canada. Can J Clin Pharmacol 2003;10:11-6.
12. Leung DY. Atopic dermatitis: immunobiology and treatment with immune modulators. Clin Exp Immunol 1997;107 Suppl 1:25-30.
13. Jolles S, Hughes J, Rustin M. Intracellular interleukin-4 profiles during high-dose intravenous immunoglobulin treatment of therapy-resistant atopic dermatitis. J Am Acad Dermatol 1999;40:121-3.
14. Jee SJ, Kim JH, Baek HS, Lee HB, Oh JW. Long-term efficacy of intravenous immunoglobulin therapy for moderate to severe childhood atopic dermatitis. Allergy Asthma Immunol Res 2011;3:89-95.